Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia

Figure 3

Mean weight change from baseline for patients who entered the OLE study, by prior double-blind phase 3 study treatment. 06 010 is the OLE of the DB phase 3 trials (placebo patients in the DB phase were initiated on active treatment at the start of the OLE phase). DB, double-blind; OLE, open-label extension; SEM, standard error of the mean; SXB, sodium oxybate.

Back to article page